Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea

Jo, Hyun Jin; Lee, Hye Seung; Kim, Nayoung; Nam, Ryoung Hee; Chang, Hyun; Kim, Min Soo; Kim, Sung Eun; Oh, Jane C; Lee, Dong Hoon; Jung, Hyun Chae

doi:10.5056/jnm.2013.19.2.210

Cited by 8 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a study directed to evaluate the regression of BE with proton pump inhibitors treatment showed that, in patients with lower degree of CDX2 expression, together with other markers, the chance for reversibility of BE was higher [26]. This study corroborates the role of CDX2 in esophageal epithelial pathologic differentia-tion and suggests biomarkers could predict the reversibility of this process.…”

Section: Discussionsupporting

confidence: 61%

CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma

Streher¹,

Campos²,

Mazzini³

et al. 2014

JCT

View full text Add to dashboard Cite

Background: Patients with Barrett's esophagus have an increased risk of developing esophageal adenocarcinoma. Our purpose was to determine CDX2 expression in esophageal mucosa and establish a correlation between this marker and the progression of disease. Methods: We analyzed biopsies and surgical specimens from 150 patients who were divided into five groups according to histopathological diagnosis: G1, normal mucosa (n = 29); G2, esophagitis (n = 19); G3, columnar epithelium without intestinal metaplasia (n = 26); G4, Barrett's esophagus (n = 32), and G5, adenocarcinoma (n = 44). Immuno-histochemical determination of CDX2 expression was considered positive in the presence of nuclear staining. Results: No CDX2 expression was detected in the G1 or G3 groups; 5% of G2, 62.5% of G4 and 70.5% of G5 patients were CDX2 positive. There was a statistically significant difference between the G4 and G5 groups compared to the G1, G2 and G3 (p < 0.05). Conclusions: CDX2 expression was observed among patients with Barrett's esophagus and adenocarcinoma compared to other groups. CDX2 was not expressed in the phases preceding Barrett's esophagus, but there was no linear correlation between CDX2 expression and metaplasia-adenocarcinoma progression.

show abstract

Section: Discussionsupporting

confidence: 61%

CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma

Streher¹,

Campos²,

Mazzini³

et al. 2014

JCT

View full text Add to dashboard Cite

show abstract

“…10 And, the hiatal hernia was endoscopically identified when the distance from the esophagogastric junction to the diaphragmatic impingement was more than 1 cm. 11 One expert endoscopist (N.K.)…”

Section: Gastroscopymentioning

confidence: 99%

Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients With Gastroesophageal Reflux Disease

Kim

et al. 2015

J Neurogastroenterol Motil

Self Cite

View full text Add to dashboard Cite

Background/Aims Proton pump inhibitors (PPIs) are widely used in the treatment of gastroesophageal reflux disease (GERD). However, some patients fail to respond to PPI therapy. We investigated the efficacy of response to PPI therapy in patients with GERD symptoms. Methods A total of 179 subjects with GERD symptoms were prospectively enrolled and diagnosed with non-erosive reflux disease (NERD, n = 100) and erosive reflux disease (n = 79) by gastroscopy and Bernstein test and/or 24-hour esophageal pH testing. Subjects then received a standard dose of daily PPI therapy for at least 4 weeks. PPI therapy response was evaluated using questionnaires including questions about demographics, GERD symptoms, GERD impact scale, Epworth sleepiness scale, Pittsburgh sleep quality index (PSQI), hospital anxiety and depression scale, and abbreviated version of the World Health Organization quality of life scale. Results The rates of complete (≥ 80%), satisfactory (≥ 50%), partial (< 50%), and refractory response in the 179 participants were 41.3%, 30.2%, 18.4%, and 10.1%, respectively. Thus, overall response rate (complete and satisfactory responses) was 71.5%. Multivariate analysis showed body mass index < 23 kg/m 2 (OR, 2.20; 95% CI, 1.12–4.34), higher total PSQI score (OR, 1.20; 95% CI, 1.05–1.35), history of psychotherapy or neuropsychiatric medication (OR, 2.44; 95% CI, 1.23–4.85), and NERD (OR, 3.30; 95% CI, 1.54–7.11) were associated with poor response to PPI therapy. Conclusions Psychological factors, sleep dysfunction, body mass index < 23 kg/m 2 , and NERD seem to be the major factors that lead to a poor response to PPI treatment in patients with GERD symptoms.

show abstract

Sex Difference of Esophageal Cancer: Esophageal Squamous Cell Carcinoma vs. Esophageal Adenocarcinoma

Kim¹

2022

Sex/Gender-Specific Medicine in the Gastrointestinal Diseases

View full text Add to dashboard Cite

Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea

Cited by 8 publications

References 43 publications

CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma

CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma

Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients With Gastroesophageal Reflux Disease

Sex Difference of Esophageal Cancer: Esophageal Squamous Cell Carcinoma vs. Esophageal Adenocarcinoma

Contact Info

Product

Resources

About